Vifor Pharma has given commercialization rights to Pfizer. | Courtesy of Shutterstock
+ Regulatory
Amanda Rupp | Jun 11, 2016

Vifor Pharma grants Pfizer commercialization rights

Vifor Pharma, a company under the Galenica group, recently announced that it has broadened its Erythropoiesis Stimulating Agent (ESA) portfolio by granting the commercialization license rights within the U.S. to Retacrit from Pfizer.

Retacrit is Pfizer’s proposed epoetin alfa biosimilar dedicated to nephrology. Pfizer originally submitted a Biologics License Application (BLA) through one of its companies, Hospira. This application was sent to the U.S. Food and Drug Administration (FDA) during December 2014.

As of now, Retacrit will be reviewed to determine its safety and effectiveness in treating anemia that is associated with renal failure, chronic kidney disease (CKD) and chemotherapy.

When Retacrit is approved, Vifor Pharma will be able to provide a short-acting ESA specifically for the U.S. dialysis market. This could benefit countless patients living throughout the U.S.

Vifor Pharma, based in Zurich, Switzerland, has a growing worldwide presence as well as a wide network of partners and affiliates. It is a global leader that is known for finding, creating, producing and selling pharmaceutical products that treat iron deficiencies.

Vifor’s diverse portfolio includes prescription medicines and over-the-counter products to benefit patients. It uses science and worldwide resources to provide therapies that will lengthen and improve the lives of patients with a variety of health struggles.

Organizations in this story

More News